Xinru Wang

This study designs genetically encoded miniproteins to modulate FAK kinase activity, showing they can inhibit or activate FAK in vitro and in cells, and adapt them to target other kinases.

This study develops a de novo insulin receptor agonist, RF-409, which effectively treats severe insulin resistance in a mouse model by activating a mutant receptor and improving glucose homeostasis.

This paper designs a de novo Tie2 binder that activates the Angiopoietin-Tie2 pathway without integrin engagement, showing improved therapeutic potential in a mouse model of ARDS.

This paper demonstrates that AI-designed receptor modulators can drive efficient human fibroblast-to-muscle transdifferentiation by rewiring extracellular signaling.

This paper designs synthetic insulin receptor agonists that modulate receptor conformation and signaling, showing improved potency and activity in disease mutants.

This paper designs potent small protein inhibitors of C. difficile toxin B using deep learning and Rosetta, showing high affinity and stability for potential clinical use.

The paper introduces a multispectral imaging approach for live-cell imaging, enabling accurate unmixing of low signal-to-noise ratio data at video rates.

The paper develops RFdiffusion to generate protein binders for IDPs/IDRs, achieving nanomolar affinity and functional applications in amylin and IL2RG.

The paper designs de novo proteins called NeoNectins that specifically bind integrin α5β1, enhancing cell attachment and tissue integration in biomaterials.

This paper presents computational methods for designing GPCR-binding miniproteins and validates them through high-throughput screening, producing agonists and antagonists for multiple GPCRs.

The paper designs EndoTags to trigger endocytosis and degradation of target proteins, enabling tissue-specific targeting and therapeutic applications.